用TADF指导修改内分泌网膜向光敏感剂,以实现高效的光动力免疫疗法
Jiaxuan Song1, Hao Fang1, Xudong Wang2
1School of Pharmacy, Shandong University, Jinan, 250100, P. R. China.
Small (Weinheim an der Bergstrasse, Germany)
|September 5, 2024
概括
研究人员开发了新型的光敏感剂,准了内质网膜,以增强瘤免疫治疗. 这些药物有效地激活免疫细胞死亡,逆转免疫抑制瘤微环境,并抑制瘤生长.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 材料科学 材料科学 材料科学
背景情况:
- 细胞内膜网膜 (ER) 向的光敏化剂 (PS) 激活免疫细胞死亡 (ICD) 用于瘤免疫治疗.
- 目前针对ER的PS面临着诸如缓慢的系统间交叉 (ISC),不稳定的兴奋状态,低反应性氧物种 (ROS) 生产和免疫抑制性瘤微环境 (ITME) 等挑战.
研究的目的:
- 设计和合成基于香的新型氨酸PS,以优化激发状态特征,以改善光动力免疫疗法.
- 调查这些修改PS在激活ICD和逆转ITME方面的有效性.
主要方法:
- 利用热激活延迟光 (TADF) 分子设计原则来修改基于香的氨酸PS.
- 电子和几何调节PS来增强ISC,延长激发状态寿命,并促进ROS生成.
- 评估了ROS产量,ER向,ER压力诱导和ICD激活在体外和体内.
主要成果:
- 修改后的PS显著改善了激发状态特征,包括100倍更长的激发状态寿命和与原始XCy.Cy相比,汽车-XCy的ROS收益率高225%.
- 汽车XCy PS有效地诱导了ER压力并激活了ICD.
- 观察到增强的抗原呈现,树突细胞成熟和细胞毒性T淋巴细胞透,导致ITME的逆转.
结论:
- 激发状态特征的TADF引导调制是开发强效光动力免疫疗法药物的可行策略.
- 开发的 car-XCy PS 通过克服 ITME 的局限性,显示出治疗初级和远程瘤的巨大潜力.
更多相关视频
相关概念视频
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.


